Verastem, Inc. Presents New Data On Mesothelioma Programs At The 12th Meeting

Professor Raphael Bueno, M.D., Chief of Thoracic Surgery, Brigham and Women's Hospital , Boston and Principal Investigator of Verastem's ongoing Window of Opportunity study presented preliminary clinical results in an oral presentation. The study is evaluating the biomarker response to VS-6063 , an oral small molecule that targets cancer stem cells through the inhibition of focal adhesion kinase in patients with resectable pleural mesothelioma.

http://ift.tt/1twrUmY